In a prespecified analysis of the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) trial that examined data from 5711 patients with a recent myocardial infarction (<12 months), evolocumab reduced the incidence of the primary endpoint (a composite of CV death, AMI, stroke, coronary revascularization, or hospitalization for unstable angina) and key secondary endpoint (a composite of CV death, AMI, or stroke) by 19% and 25%, respectively [111]. The gene discussed is PCSK9; the disease is myocardial infarction.